Indications › Diabetes (unspecified) › liraglutide

liraglutide in diabetes (unspecified)

liraglutide is not approved in the US for diabetes (unspecified), and has 63 trials on file here in this condition. 52 of them are phase 3 or later. No trial here has a completion date still in the future, so this is a closed body of work rather than an active programme. Being studied in a condition is not the same as being approved for it; most such programmes end without an approval.

63 registered trials study liraglutide (Saxenda, Victoza, Xultophy) in diabetes (unspecified). None has a scheduled reporting date on file.

Trials on file: 63
Active: 0
Active phase 3: 0
Participants in active trials: 0
Sponsors: 10
Scheduled readouts: 0

All trials on file

Every registered trial of liraglutide grouped under diabetes (unspecified), largest first. Grouping follows the registry’s own condition wording.

Trial	Status	Phase	Sponsor
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results NCT01179048	Completed	P3	Novo Nordisk A/S
Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes NCT02730377	Completed	P4	Novo Nordisk A/S
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes NCT01336023	Completed	P3	Novo Nordisk A/S
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes NCT01836523	Completed	P3	Novo Nordisk A/S
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together NCT00318461	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00318422	Completed	P3	Novo Nordisk A/S
A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus NCT02501161	Completed	P3	Novo Nordisk A/S
The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes NCT00856986	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00614120	Completed	P3	Novo Nordisk A/S
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes NCT02098395	Completed	P3	Novo Nordisk A/S
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus. NCT02607306	Completed	P3	Novo Nordisk A/S
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c NCT00294723	Terminated	P3	Novo Nordisk A/S
A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) NCT03172494	Completed	P3	Novo Nordisk A/S
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus NCT00700817	Completed	P3	Novo Nordisk A/S
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. NCT02505334	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00331851	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00333151	Completed	P3	Novo Nordisk A/S
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus NCT01952145	Completed	P3	Novo Nordisk A/S
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus NCT02420262	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00518882	Completed	P3	Novo Nordisk A/S
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD) NCT03175120	Completed	P3	Novo Nordisk A/S
The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes NCT01617434	Completed	P3	Novo Nordisk A/S
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy NCT01676116	Completed	P3	Novo Nordisk A/S
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy NCT01618162	Completed	P3	Novo Nordisk A/S
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms NCT02298192	Completed	P3	Novo Nordisk A/S
A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus NCT02773368	Completed	P3	Novo Nordisk A/S
Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin NCT01388361	Completed	P3	Novo Nordisk A/S
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes NCT01392573	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin NCT01907854	Completed	P4	Novo Nordisk A/S
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes NCT01973231	Completed	P4	Novo Nordisk A/S
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00393718	Completed	P3	Novo Nordisk A/S
Saxenda in Obesity Services (STRIVE Study) NCT03036800	Completed	P4	University of Leicester
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes NCT02008682	Completed	P4	Novo Nordisk A/S
Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone NCT01512108	Completed	P3	Novo Nordisk A/S
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification NCT01664247	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes NCT01917656	Completed	P4	Novo Nordisk A/S
A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function NCT02443155	Completed	P2	Novo Nordisk A/S
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. NCT02964247	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment NCT01620489	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00395746	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes NCT01572740	Completed	P3	Novo Nordisk A/S
Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes NCT00154414	Completed	P2	Novo Nordisk A/S
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent NCT01511198	Completed	P2	Novo Nordisk A/S
A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs NCT02911948	Completed	P3	Novo Nordisk A/S
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease NCT04146155	Unknown	P4	Second Affiliated Hospital, Zhejiang University, School of Medicine
Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes NCT01509755	Completed	P2	Novo Nordisk A/S
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes NCT00154401	Completed	P2	Novo Nordisk A/S
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004) NCT02492763	Terminated	P2	Merck Sharp & Dohme LLC
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study NCT01966978	Completed	P4	University of Texas Southwestern Medical Center
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) NCT01234649	Completed	P3	Woman's
IDegLira HIGH Trial NCT03737240	Completed	P3	Emory University
Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes NCT01511172	Completed	P2	Novo Nordisk A/S
Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes NCT01541215	Completed	P3	Novo Nordisk A/S
A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin NCT02205528	Completed	P2	Novo Nordisk A/S
The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes NCT01795248	Completed	P4	Tina Vilsboll
The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus NCT00620282	Completed	P3	Novo Nordisk A/S
Liraglutide as add-on to Insulin in Type 1 Diabetes NCT02092896	Completed	P3	Hvidovre University Hospital
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes NCT01508949	Completed	P2	Novo Nordisk A/S
A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification NCT02100475	Completed	P3	Novo Nordisk A/S
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes NCT00993720	Completed	P2/P3	Hvidovre University Hospital

See the full record for liraglutide, or every molecule being studied in diabetes (unspecified). These are registered trials, nothing more. Most drugs tested in a new condition never get approved for it, and plenty of these will report nothing useful.